Ocugen, Inc (OCGN) is a leading biotechnology business based in the US. It opened the day at USD$0.3232 after a previous close of USD$0.3193. During the day the price has varied from a low of USD$0.3013 to a high of USD$0.3417. The latest price was USD$0.3119 (25 minute delay). Ocugen is listed on the NASDAQ and employs 16 staff. All prices are listed in US Dollars.
About our promoted products: Our 'promoted' products are presented as a result of a commercial advertising arrangement or to highlight a particular feature. Promoted products are not a recommendation, an indication a product is the best in its category, nor represent all products in the market. It is important to compare your options and find the right product for you. Some of our promoted products are CFD providers. CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment
|52-week range||USD$0.185 - USD$0.9577|
|50-day moving average||USD$0.3081|
|200-day moving average||USD$0.3347|
|Wall St. target price||USD$0.9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.8349|
|1 week (2020-11-16)||10.02%|
|1 month (2020-10-23)||-3.44%|
|3 months (2020-08-21)||-33.92%|
|6 months (2020-05-22)||-0.03%|
|1 year (2019-11-22)||10.41%|
|2 years (2018-11-23)||-41.18%|
|3 years (2017-11-22)||-84.64%|
|5 years (2015-11-23)||-91.04%|
Valuing Ocugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ocugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ocugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Ocugen shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
There are currently 5.5 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 11.5% down from 6.2 million last month.
There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.
Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 5.0 million). Ocugen's SIR currently stands at 1.09. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 1090 shares are currently held short.
However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 30 shares are currently held short) or 0.0348% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.
Steps to owning and managing HYLN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASAN, with 24-hour and historical pricing before you buy.
Steps to owning and managing Merck shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Mylan shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Johnson And Johnson shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Abbott Laboratories shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Aurinia Pharmaceuticals shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing VBI Vaccines shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Cara Therapeutics shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Co-Diagnostics shares, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.